Two facts confirm little FOMO at moment. 1)50 million share offering has been peddled since beginning of month, has been available since mid month and per OTC share count, only 400,128 shares have sold so far. 2) Volume atm is low. That said, it's not a problem if RDGL has enough cash on hand to get to FDA approving a small human trial study, at which point raising money for a small human study won't be an issue. So that is the unanswered question: can RDGL make it to next step with cash on hand?
News 
Market Data 
Discover 
AI
